Basic details of study participants, prevalence of pain, and prevalence of PDPN
| Population break down . | n (%) . |
|---|---|
| Practice population (“list size”) | |
| Total | 8,531 |
| Diabetes register | |
| Total | 385 |
| Known to have type 1 diabetes | 28 |
| Known to have type 2 diabetes | 354 |
| Found not to have diabetes | 3 |
| Deceased | 1 |
| Study sample (phase 1) | |
| Potentially eligible | 353 |
| Nonresponders (25) and those unable to respond (2) | 27 |
| Responders | 326 (92.7) |
| Reported pain | 208 (63.8) |
| Did not report pain | 118 (36.2) |
| Study sample (phase 2) | |
| Eligible | 326 |
| Attended for assessment | 269 (82.5) |
| Neuropathic pain | 51 (19.0) |
| Nonneuropathic pain | 99 (36.8) |
| Mixed pain | 20 (7.4) |
| No pain | 99 (36.8) |
| Population break down . | n (%) . |
|---|---|
| Practice population (“list size”) | |
| Total | 8,531 |
| Diabetes register | |
| Total | 385 |
| Known to have type 1 diabetes | 28 |
| Known to have type 2 diabetes | 354 |
| Found not to have diabetes | 3 |
| Deceased | 1 |
| Study sample (phase 1) | |
| Potentially eligible | 353 |
| Nonresponders (25) and those unable to respond (2) | 27 |
| Responders | 326 (92.7) |
| Reported pain | 208 (63.8) |
| Did not report pain | 118 (36.2) |
| Study sample (phase 2) | |
| Eligible | 326 |
| Attended for assessment | 269 (82.5) |
| Neuropathic pain | 51 (19.0) |
| Nonneuropathic pain | 99 (36.8) |
| Mixed pain | 20 (7.4) |
| No pain | 99 (36.8) |